S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
AI Stock Caught Trading Under Secret Name (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
The Retirement of Your Dreams Awaits You… (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
The Retirement of Your Dreams Awaits You… (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
AI Stock Caught Trading Under Secret Name (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
The Retirement of Your Dreams Awaits You… (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
The Retirement of Your Dreams Awaits You… (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
AI Stock Caught Trading Under Secret Name (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
The Retirement of Your Dreams Awaits You… (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
The Retirement of Your Dreams Awaits You… (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
AI Stock Caught Trading Under Secret Name (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
The Retirement of Your Dreams Awaits You… (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
The Retirement of Your Dreams Awaits You… (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024

Ultragenyx Pharmaceutical (RARE) Competitors

$49.48
+0.60 (+1.23%)
(As of 02/23/2024 ET)

RARE vs. FOLD, AXSM, BHVN, ACAD, RYZB, MRTX, CBAY, INSM, ARWR, and VKTX

Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Amicus Therapeutics (FOLD), Axsome Therapeutics (AXSM), Biohaven (BHVN), ACADIA Pharmaceuticals (ACAD), RayzeBio (RYZB), Mirati Therapeutics (MRTX), CymaBay Therapeutics (CBAY), Insmed (INSM), Arrowhead Pharmaceuticals (ARWR), and Viking Therapeutics (VKTX). These companies are all part of the "pharmaceutical preparations" industry.

Ultragenyx Pharmaceutical vs.

Amicus Therapeutics (NASDAQ:FOLD) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, community ranking, dividends and valuation.

Amicus Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.

96.4% of Ultragenyx Pharmaceutical shares are held by institutional investors. 2.1% of Amicus Therapeutics shares are held by company insiders. Comparatively, 6.8% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than Amicus Therapeutics. MarketBeat recorded 18 mentions for Ultragenyx Pharmaceutical and 17 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 0.52 beat Ultragenyx Pharmaceutical's score of 0.25 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amicus Therapeutics
4 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ultragenyx Pharmaceutical
7 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Amicus Therapeutics has a net margin of -46.61% compared to Amicus Therapeutics' net margin of -139.70%. Ultragenyx Pharmaceutical's return on equity of -147.61% beat Amicus Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Amicus Therapeutics-46.61% -147.61% -23.79%
Ultragenyx Pharmaceutical -139.70%-477.39%-46.28%

Amicus Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amicus Therapeutics$329.23M12.05-$236.57M-$0.59-22.93
Ultragenyx Pharmaceutical$434.25M9.36-$606.64M-$8.33-5.94

Ultragenyx Pharmaceutical received 287 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. Likewise, 77.08% of users gave Ultragenyx Pharmaceutical an outperform vote while only 73.38% of users gave Amicus Therapeutics an outperform vote.

CompanyUnderperformOutperform
Amicus TherapeuticsOutperform Votes
510
73.38%
Underperform Votes
185
26.62%
Ultragenyx PharmaceuticalOutperform Votes
797
77.08%
Underperform Votes
237
22.92%

Amicus Therapeutics currently has a consensus price target of $17.20, suggesting a potential upside of 27.12%. Ultragenyx Pharmaceutical has a consensus price target of $92.20, suggesting a potential upside of 86.19%. Given Amicus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Amicus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amicus Therapeutics
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Ultragenyx Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Summary

Ultragenyx Pharmaceutical beats Amicus Therapeutics on 11 of the 18 factors compared between the two stocks.


Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RARE vs. The Competition

MetricUltragenyx PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.06B$6.70B$5.03B$7.52B
Dividend YieldN/A2.72%2.92%3.86%
P/E Ratio-5.9410.83101.2616.11
Price / Sales9.36143.393,103.9555.29
Price / CashN/A18.1888.3852.42
Price / Book9.844.564.364.63
Net Income-$606.64M$156.18M$112.59M$207.21M
7 Day Performance1.14%1.07%0.86%-0.98%
1 Month Performance11.24%10.55%6.85%3.29%
1 Year Performance11.34%1.27%8.77%3.69%

Ultragenyx Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FOLD
Amicus Therapeutics
3.6639 of 5 stars
$13.70
-0.4%
$17.20
+25.5%
+3.8%$4.02B$329.23M-23.22484Upcoming Earnings
Insider Selling
Analyst Revision
News Coverage
AXSM
Axsome Therapeutics
4.6819 of 5 stars
$81.14
-12.6%
$114.30
+40.9%
+27.5%$3.84B$50.04M-17.91502Analyst Report
Analyst Revision
High Trading Volume
BHVN
Biohaven
0.9576 of 5 stars
$47.24
-4.6%
$44.50
-5.8%
+203.7%$3.79B$462.51M-6.59202Analyst Report
ACAD
ACADIA Pharmaceuticals
4.3335 of 5 stars
$24.85
-1.0%
$36.26
+45.9%
+29.7%$4.08B$517.23M-27.01580Upcoming Earnings
RYZB
RayzeBio
0.1841 of 5 stars
$62.49
+0.1%
$31.33
-49.9%
N/A$3.74BN/A0.0088Upcoming Earnings
News Coverage
MRTX
Mirati Therapeutics
0.3308 of 5 stars
$58.70
-0.2%
$60.00
+2.2%
+27.7%$4.12B$12.44M-4.80587Upcoming Earnings
Analyst Report
News Coverage
High Trading Volume
CBAY
CymaBay Therapeutics
3.5951 of 5 stars
$32.20
+0.1%
$26.73
-17.0%
+292.6%$3.65BN/A-35.0060Analyst Report
INSM
Insmed
3.3942 of 5 stars
$29.21
-1.0%
$44.90
+53.7%
+33.9%$4.22B$280.82M-5.54373Earnings Report
Analyst Downgrade
News Coverage
ARWR
Arrowhead Pharmaceuticals
4.6692 of 5 stars
$29.22
-0.9%
$51.25
+75.4%
-3.5%$3.62B$181.74M-10.51525Positive News
VKTX
Viking Therapeutics
3.076 of 5 stars
$35.74
-1.3%
$34.00
-4.9%
+226.8%$3.59BN/A-38.8527Analyst Report

Related Companies and Tools

This page (NASDAQ:RARE) was last updated on 2/24/2024 by MarketBeat.com Staff